Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 seqWell and Gencove Announce Partnership | Contract Pharma
Breaking News, Collaborations & Alliances

seqWell and Gencove Announce Partnership

To combine technology and analysis software to provide genomic researchers an end-to-end solution for low-pass whole genome sequencing and genotype imputation

seqWell and Gencove today announced a partnership to bring together seqWell’s plexWell library preparation technology and Gencove’s imputation and analysis software to provide genomic researchers a powerful and scalable end-to-end solution for low-pass whole genome sequencing and genotype imputation.

Low-pass sequencing technologies offer a high-throughput, cost-efficient and accurate solution for large-scale genomic projects that historically have relied on genotyping microarrays. Gencove’s cloud-based imputation software calls variants with high accuracy across the whole genome resulting in more data, greater statistical power, and enhanced variant discovery capabilities than genotyping arrays.

The adoption of this approach has been driven partly by lower costs of raw sequencing data, but also requires robust, reliable and scalable methods of multiplexed library preparation. plexWell technology from seqWell overcomes challenges of library preparation workflow scalability through massively paralleled multiplexing of samples. Well-balanced libraries containing hundreds to thousands of samples can be prepared and sequenced in a single day using low-pass, next generation sequencing (NGS). 

“Our experience with plexWell technology is that it makes library prep both more scalable and user-friendly,” according to Joe Pickrell, chief executive officer and co-founder of Gencove.  “This partnership will enable anyone with an Illumina sequencer to efficiently replace genotyping arrays with low-pass whole genome sequencing across applications, including genomic selection, marker assisted selection, QTL mapping and genome-wide association studies.”

“The combined throughput, quality and power of plexWell technology and Gencove software create a uniquely enabling, complete solution that allows researcher to harness the full potential of NGS for genotyping human, animal and plant genomes,” says Joseph Mellor, chief executive officer and founder of seqWell, Inc. “We are excited about making cost-effective, large-scale, low-pass whole genome sequencing a reality for the genomics community”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters